11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

By J. Rinne, D. Brooks, Martin Rossor, Nick C Fox, M. Grundman. Lancet Neurology, 2010

733 citations recorded by the source corpus.

Subfields: Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/279bc3d68ffd2f155b4b9842f483e86210f4775f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. Reisa A. Sperling
2. Nick C Fox
3. William E. Klunk
4. Keith A. Johnson
5. E. Karran
6. M. Mercken
7. B. de Strooper
8. Randy L. Buckner

In Psychiatry and Mental health

1. Reisa A. Sperling
2. Nick C Fox
3. William E. Klunk
4. Keith A. Johnson

Citations in the corpus

• Brain imaging in Alzheimer disease. (2012, background): “In support of this statement, the ability of amyloid PET to show an amyloid-lowering effect of passive immunotherapy in humans has already been reported (Rinne et al. 2010).”
• The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics (2011, background): “Another study measured the effects of bapineuzumab on deposited amyloid-β levels in the brain using the PET ligand PI”